What is the projected market valuation for Age-Related Macular Degeneration by 2035?

The projected market valuation for Age-Related Macular Degeneration is expected to reach 20.59 USD Billion by 2035. Read More

What was the market valuation for Age-Related Macular Degeneration in 2024?

The overall market valuation for Age-Related Macular Degeneration was 8.45 USD Billion in 2024. Read More

What is the expected CAGR for the Age-Related Macular Degeneration market from 2025 to 2035?

The expected CAGR for the Age-Related Macular Degeneration market during the forecast period 2025 - 2035 is 8.43%. Read More

Which treatment method is projected to have the highest market value by 2035?

Anti-VEGF Therapy is projected to have the highest market value, expected to grow from 3.5 USD Billion to 8.5 USD Billion. Read More

What are the key players in the Age-Related Macular Degeneration market?

Key players in the market include Regeneron Pharmaceuticals, Novartis, Roche, Bayer, Pfizer, Alcon, Horizon Therapeutics, Apellis Pharmaceuticals, and Santen Pharmaceutical. Read More

How does the market for Dry Age-Related Macular Degeneration compare to Wet Age-Related Macular Degeneration?

The market for Dry Age-Related Macular Degeneration is expected to grow from 3.38 USD Billion to 8.0 USD Billion, while Wet Age-Related Macular Degeneration is projected to increase from 4.23 USD Billion to 9.8 USD Billion. Read More

What distribution channel is anticipated to show significant growth by 2035?

Online Pharmacies are anticipated to show significant growth, with a projected increase from 2.12 USD Billion to 5.3 USD Billion. Read More

Which patient demographic is expected to dominate the Age-Related Macular Degeneration market?

Elderly Patients are expected to dominate the market, with a projected growth from 3.5 USD Billion to 8.5 USD Billion. Read More

What is the expected market value for Nutritional Supplements by 2035?

The expected market value for Nutritional Supplements is projected to rise from 2.45 USD Billion to 6.09 USD Billion by 2035. Read More

How does the market for Optical Clinics compare to Retail Pharmacies in terms of growth?

The market for Optical Clinics is expected to grow from 1.69 USD Billion to 4.05 USD Billion, whereas Retail Pharmacies are projected to increase from 2.12 USD Billion to 5.12 USD Billion. Read More

Age Related Macular Degeneration Market

ID: MRFR/Pharma/4281-CR

200 Pages

Vikita Thakur

Last Updated: April 24, 2026

Age-Related Macular Degeneration Market Research Report: Size, Share, Trend Analysis By Types (Dry Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration, Geographic Atrophy), By Treatment Method (Anti-VEGF Therapy, Photodynamic Therapy, Laser Surgery, Nutritional Supplements), By Distribution Channel (Hospitals, Optical Clinics, Retail Pharmacies, Online Pharmacies), By Patient Demographics (Elderly Patients, Middle-Aged Patients, Genetic Predisposition) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Age Related Macular Degeneration Market Infographic

Summary Table of Contents Segmentation Methodology Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1.1 EXECUTIVE SUMMARY
1.1.1 Market Overview
1.1.2 Key Findings
1.1.3 Market Segmentation
1.1.4 Competitive Landscape
1.1.5 Challenges and Opportunities
1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
2.1 MARKET INTRODUCTION
2.1.1 Definition
2.1.2 Scope of the study
2.1.2.1 Research Objective
2.1.2.2 Assumption
2.1.2.3 Limitations
2.2 RESEARCH METHODOLOGY
2.2.1 Overview
2.2.2 Data Mining
2.2.3 Secondary Research
2.2.4 Primary Research
2.2.4.1 Primary Interviews and Information Gathering Process
2.2.4.2 Breakdown of Primary Respondents
2.2.5 Forecasting Model
2.2.6 Market Size Estimation
2.2.6.1 Bottom-Up Approach
2.2.6.2 Top-Down Approach
2.2.7 Data Triangulation
2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
3.1 MARKET DYNAMICS
3.1.1 Overview
3.1.2 Drivers
3.1.3 Restraints
3.1.4 Opportunities
3.2 MARKET FACTOR ANALYSIS
3.2.1 Value chain Analysis
3.2.2 Porter's Five Forces Analysis
3.2.2.1 Bargaining Power of Suppliers
3.2.2.2 Bargaining Power of Buyers
3.2.2.3 Threat of New Entrants
3.2.2.4 Threat of Substitutes
3.2.2.5 Intensity of Rivalry
3.2.3 COVID-19 Impact Analysis
3.2.3.1 Market Impact Analysis
3.2.3.2 Regional Impact
3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
4.1 Healthcare, BY Type (USD Billion)
4.1.1 Dry Age-Related Macular Degeneration
4.1.2 Wet Age-Related Macular Degeneration
4.1.3 Geographic Atrophy
4.2 Healthcare, BY Treatment Method (USD Billion)
4.2.1 Anti-VEGF Therapy
4.2.2 Photodynamic Therapy
4.2.3 Laser Surgery
4.2.4 Nutritional Supplements
4.3 Healthcare, BY Distribution Channel (USD Billion)
4.3.1 Hospitals
4.3.2 Optical Clinics
4.3.3 Retail Pharmacies
4.3.4 Online Pharmacies
4.4 Healthcare, BY Patient Demographics (USD Billion)
4.4.1 Elderly Patients
4.4.2 Middle-Aged Patients
4.4.3 Genetic Predisposition
4.5 Healthcare, BY Region (USD Billion)
4.5.1 North America
4.5.1.1 US
4.5.1.2 Canada
4.5.2 Europe
4.5.2.1 Germany
4.5.2.2 UK
4.5.2.3 France
4.5.2.4 Russia
4.5.2.5 Italy
4.5.2.6 Spain
4.5.2.7 Rest of Europe
4.5.3 APAC
4.5.3.1 China
4.5.3.2 India
4.5.3.3 Japan
4.5.3.4 South Korea
4.5.3.5 Malaysia
4.5.3.6 Thailand
4.5.3.7 Indonesia
4.5.3.8 Rest of APAC
4.5.4 South America
4.5.4.1 Brazil
4.5.4.2 Mexico
4.5.4.3 Argentina
4.5.4.4 Rest of South America
4.5.5 MEA
4.5.5.1 GCC Countries
4.5.5.2 South Africa
4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
5.1 Competitive Landscape
5.1.1 Overview
5.1.2 Competitive Analysis
5.1.3 Market share Analysis
5.1.4 Major Growth Strategy in the Healthcare
5.1.5 Competitive Benchmarking
5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
5.1.7 Key developments and growth strategies
5.1.7.1 New Product Launch/Service Deployment
5.1.7.2 Merger & Acquisitions
5.1.7.3 Joint Ventures
5.1.8 Major Players Financial Matrix
5.1.8.1 Sales and Operating Income
5.1.8.2 Major Players R&D Expenditure. 2023
5.2 Company Profiles
5.2.1 Regeneron Pharmaceuticals (US)
5.2.1.1 Financial Overview
5.2.1.2 Products Offered
5.2.1.3 Key Developments
5.2.1.4 SWOT Analysis
5.2.1.5 Key Strategies
5.2.2 Novartis (CH)
5.2.2.1 Financial Overview
5.2.2.2 Products Offered
5.2.2.3 Key Developments
5.2.2.4 SWOT Analysis
5.2.2.5 Key Strategies
5.2.3 Roche (CH)
5.2.3.1 Financial Overview
5.2.3.2 Products Offered
5.2.3.3 Key Developments
5.2.3.4 SWOT Analysis
5.2.3.5 Key Strategies
5.2.4 Bayer (DE)
5.2.4.1 Financial Overview
5.2.4.2 Products Offered
5.2.4.3 Key Developments
5.2.4.4 SWOT Analysis
5.2.4.5 Key Strategies
5.2.5 Pfizer (US)
5.2.5.1 Financial Overview
5.2.5.2 Products Offered
5.2.5.3 Key Developments
5.2.5.4 SWOT Analysis
5.2.5.5 Key Strategies
5.2.6 Alcon (CH)
5.2.6.1 Financial Overview
5.2.6.2 Products Offered
5.2.6.3 Key Developments
5.2.6.4 SWOT Analysis
5.2.6.5 Key Strategies
5.2.7 Horizon Therapeutics (IE)
5.2.7.1 Financial Overview
5.2.7.2 Products Offered
5.2.7.3 Key Developments
5.2.7.4 SWOT Analysis
5.2.7.5 Key Strategies
5.2.8 Apellis Pharmaceuticals (US)
5.2.8.1 Financial Overview
5.2.8.2 Products Offered
5.2.8.3 Key Developments
5.2.8.4 SWOT Analysis
5.2.8.5 Key Strategies
5.2.9 Santen Pharmaceutical (JP)
5.2.9.1 Financial Overview
5.2.9.2 Products Offered
5.2.9.3 Key Developments
5.2.9.4 SWOT Analysis
5.2.9.5 Key Strategies
5.3 Appendix
5.3.1 References
5.3.2 Related Reports
6 LIST OF FIGURES
6.1 MARKET SYNOPSIS
6.2 NORTH AMERICA MARKET ANALYSIS
6.3 US MARKET ANALYSIS BY TYPE
6.4 US MARKET ANALYSIS BY TREATMENT METHOD
6.5 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.6 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.7 CANADA MARKET ANALYSIS BY TYPE
6.8 CANADA MARKET ANALYSIS BY TREATMENT METHOD
6.9 CANADA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.10 CANADA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.11 EUROPE MARKET ANALYSIS
6.12 GERMANY MARKET ANALYSIS BY TYPE
6.13 GERMANY MARKET ANALYSIS BY TREATMENT METHOD
6.14 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.15 GERMANY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.16 UK MARKET ANALYSIS BY TYPE
6.17 UK MARKET ANALYSIS BY TREATMENT METHOD
6.18 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.19 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.20 FRANCE MARKET ANALYSIS BY TYPE
6.21 FRANCE MARKET ANALYSIS BY TREATMENT METHOD
6.22 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.23 FRANCE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.24 RUSSIA MARKET ANALYSIS BY TYPE
6.25 RUSSIA MARKET ANALYSIS BY TREATMENT METHOD
6.26 RUSSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.27 RUSSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.28 ITALY MARKET ANALYSIS BY TYPE
6.29 ITALY MARKET ANALYSIS BY TREATMENT METHOD
6.30 ITALY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.31 ITALY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.32 SPAIN MARKET ANALYSIS BY TYPE
6.33 SPAIN MARKET ANALYSIS BY TREATMENT METHOD
6.34 SPAIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.35 SPAIN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE
6.37 REST OF EUROPE MARKET ANALYSIS BY TREATMENT METHOD
6.38 REST OF EUROPE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.39 REST OF EUROPE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.40 APAC MARKET ANALYSIS
6.41 CHINA MARKET ANALYSIS BY TYPE
6.42 CHINA MARKET ANALYSIS BY TREATMENT METHOD
6.43 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.44 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.45 INDIA MARKET ANALYSIS BY TYPE
6.46 INDIA MARKET ANALYSIS BY TREATMENT METHOD
6.47 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.48 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.49 JAPAN MARKET ANALYSIS BY TYPE
6.50 JAPAN MARKET ANALYSIS BY TREATMENT METHOD
6.51 JAPAN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.52 JAPAN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE
6.54 SOUTH KOREA MARKET ANALYSIS BY TREATMENT METHOD
6.55 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.56 SOUTH KOREA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.57 MALAYSIA MARKET ANALYSIS BY TYPE
6.58 MALAYSIA MARKET ANALYSIS BY TREATMENT METHOD
6.59 MALAYSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.60 MALAYSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.61 THAILAND MARKET ANALYSIS BY TYPE
6.62 THAILAND MARKET ANALYSIS BY TREATMENT METHOD
6.63 THAILAND MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.64 THAILAND MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.65 INDONESIA MARKET ANALYSIS BY TYPE
6.66 INDONESIA MARKET ANALYSIS BY TREATMENT METHOD
6.67 INDONESIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.68 INDONESIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.69 REST OF APAC MARKET ANALYSIS BY TYPE
6.70 REST OF APAC MARKET ANALYSIS BY TREATMENT METHOD
6.71 REST OF APAC MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.72 REST OF APAC MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.73 SOUTH AMERICA MARKET ANALYSIS
6.74 BRAZIL MARKET ANALYSIS BY TYPE
6.75 BRAZIL MARKET ANALYSIS BY TREATMENT METHOD
6.76 BRAZIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.77 BRAZIL MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.78 MEXICO MARKET ANALYSIS BY TYPE
6.79 MEXICO MARKET ANALYSIS BY TREATMENT METHOD
6.80 MEXICO MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.81 MEXICO MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.82 ARGENTINA MARKET ANALYSIS BY TYPE
6.83 ARGENTINA MARKET ANALYSIS BY TREATMENT METHOD
6.84 ARGENTINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.85 ARGENTINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT METHOD
6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.90 MEA MARKET ANALYSIS
6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE
6.92 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT METHOD
6.93 GCC COUNTRIES MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.94 GCC COUNTRIES MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE
6.96 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT METHOD
6.97 SOUTH AFRICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.98 SOUTH AFRICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.99 REST OF MEA MARKET ANALYSIS BY TYPE
6.100 REST OF MEA MARKET ANALYSIS BY TREATMENT METHOD
6.101 REST OF MEA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.102 REST OF MEA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6.103 KEY BUYING CRITERIA OF HEALTHCARE
6.104 RESEARCH PROCESS OF MRFR
6.105 DRO ANALYSIS OF HEALTHCARE
6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE)
6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
6.111 HEALTHCARE, BY TREATMENT METHOD, 2024 (% SHARE)
6.112 HEALTHCARE, BY TREATMENT METHOD, 2024 TO 2035 (USD Billion)
6.113 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
6.114 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
6.115 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
6.116 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
7.1 LIST OF ASSUMPTIONS
7.1.1
7.2 North America MARKET SIZE ESTIMATES; FORECAST
7.2.1 BY TYPE, 2025-2035 (USD Billion)
7.2.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.2.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.3 US MARKET SIZE ESTIMATES; FORECAST
7.3.1 BY TYPE, 2025-2035 (USD Billion)
7.3.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.3.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.3.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.4 Canada MARKET SIZE ESTIMATES; FORECAST
7.4.1 BY TYPE, 2025-2035 (USD Billion)
7.4.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.4.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.4.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.5 Europe MARKET SIZE ESTIMATES; FORECAST
7.5.1 BY TYPE, 2025-2035 (USD Billion)
7.5.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.5.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.5.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.6 Germany MARKET SIZE ESTIMATES; FORECAST
7.6.1 BY TYPE, 2025-2035 (USD Billion)
7.6.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.6.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.6.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.7 UK MARKET SIZE ESTIMATES; FORECAST
7.7.1 BY TYPE, 2025-2035 (USD Billion)
7.7.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.7.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.7.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.8 France MARKET SIZE ESTIMATES; FORECAST
7.8.1 BY TYPE, 2025-2035 (USD Billion)
7.8.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.8.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.8.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.9 Russia MARKET SIZE ESTIMATES; FORECAST
7.9.1 BY TYPE, 2025-2035 (USD Billion)
7.9.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.9.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.9.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.10 Italy MARKET SIZE ESTIMATES; FORECAST
7.10.1 BY TYPE, 2025-2035 (USD Billion)
7.10.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.10.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.10.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.11 Spain MARKET SIZE ESTIMATES; FORECAST
7.11.1 BY TYPE, 2025-2035 (USD Billion)
7.11.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.11.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.11.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
7.12.1 BY TYPE, 2025-2035 (USD Billion)
7.12.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.12.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.12.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.13 APAC MARKET SIZE ESTIMATES; FORECAST
7.13.1 BY TYPE, 2025-2035 (USD Billion)
7.13.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.13.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.13.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.14 China MARKET SIZE ESTIMATES; FORECAST
7.14.1 BY TYPE, 2025-2035 (USD Billion)
7.14.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.14.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.14.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.15 India MARKET SIZE ESTIMATES; FORECAST
7.15.1 BY TYPE, 2025-2035 (USD Billion)
7.15.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.15.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.15.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.16 Japan MARKET SIZE ESTIMATES; FORECAST
7.16.1 BY TYPE, 2025-2035 (USD Billion)
7.16.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.16.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.16.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
7.17.1 BY TYPE, 2025-2035 (USD Billion)
7.17.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.17.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.17.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
7.18.1 BY TYPE, 2025-2035 (USD Billion)
7.18.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.18.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.18.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
7.19.1 BY TYPE, 2025-2035 (USD Billion)
7.19.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.19.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.19.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
7.20.1 BY TYPE, 2025-2035 (USD Billion)
7.20.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.20.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.20.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
7.21.1 BY TYPE, 2025-2035 (USD Billion)
7.21.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.21.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.21.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.22 South America MARKET SIZE ESTIMATES; FORECAST
7.22.1 BY TYPE, 2025-2035 (USD Billion)
7.22.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.22.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.22.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
7.23.1 BY TYPE, 2025-2035 (USD Billion)
7.23.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.23.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.23.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
7.24.1 BY TYPE, 2025-2035 (USD Billion)
7.24.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.24.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.24.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
7.25.1 BY TYPE, 2025-2035 (USD Billion)
7.25.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.25.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.25.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
7.26.1 BY TYPE, 2025-2035 (USD Billion)
7.26.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.26.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.26.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.27 MEA MARKET SIZE ESTIMATES; FORECAST
7.27.1 BY TYPE, 2025-2035 (USD Billion)
7.27.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.27.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.27.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
7.28.1 BY TYPE, 2025-2035 (USD Billion)
7.28.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.28.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.28.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
7.29.1 BY TYPE, 2025-2035 (USD Billion)
7.29.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.29.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.29.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
7.30.1 BY TYPE, 2025-2035 (USD Billion)
7.30.2 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.30.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
7.30.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion)
7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

Dry Age-Related Macular Degeneration
Wet Age-Related Macular Degeneration
Geographic Atrophy

Healthcare By Treatment Method (USD Billion, 2025-2035)

Anti-VEGF Therapy
Photodynamic Therapy
Laser Surgery
Nutritional Supplements

Healthcare By Distribution Channel (USD Billion, 2025-2035)

Hospitals
Optical Clinics
Retail Pharmacies
Online Pharmacies

Healthcare By Patient Demographics (USD Billion, 2025-2035)

Elderly Patients
Middle-Aged Patients
Genetic Predisposition

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓